News

According to the company, MMJMenu provides business management software for dispensaries and growers, enabling them to track their medical cannabis from seed to sale. WeedMaps chief web officer

Remodulin is approved for the continuous subcutaneous infusion treatment of idiopathic or heritable PAH to improve exercise tolerance and symptoms of the disease. For intravenous Remodulin, United Therapeutics

OWH’s effectiveness study, which enrolled 120 patients, is gathering information on how safe and efficacious PMIM mono-therapy for VL is at a regional level. The study will also

With the termination of the agreement, Abbott will have to provide certain forms of transition assistance to Emergent for a certain period of time and Emergent will retain

The findings were the result of research partnership between Alnylam and Medtronic and supported by CHDI. The results demonstrated that a small interfering RNA (siRNA) targeting huntingtin gene,

Following the amendment of the deal, UCB gains the flexibility to select a partner to sublicense its rights for certain territories. In addition, in return for the right

TRU-016 is a humanized anti-CD37 mono-specific protein therapeutic in development for the treatment of B-cell malignancies. Emergent will be entitled to a milestone payment of $6m with the

Levetiracetam, the generic version of UCB’s Keppra XR Tablets, is indicated as a treatment for partial onset seizures in patients over 16 years of age with epilepsy. Levetiracetam

Eprosartan Mesylate is the generic version of Abbott Laboratories’ Teveten Tablets, indicated for the treatment of hypertension. The company has been awarded 180 days of marketing exclusivity and